Antimicrobial resistance (AMR) is on a constant rise and is significantly limiting treatment options against bacterial pathogens, especially those belonging to the WHO priority list including Mycobacterium tuberculosis . Unfortunately, this trend is not matched by parallel developments of promising antibiotics due to a broken market for these life-saving drugs and numerous additional complications, which make the identification of promising antibiotic candidates exhibiting little or no cross-resistance with commonly used antibiotics extremely rare events .